Table 1 Baseline characteristics of the study population: Tehran Lipid and Glucose Study (1999–2014)
|  | Total (N = 1448) | Non-survivors (N = 305) | Survivors (N = 1143) | p-value |
|---|---|---|---|---|
Age, years | 60.9 (9.9) | 68.13 (7.7) | 58.96 (9.6) | < 0.001 |
BMI, kg/m2 | 28.2 (4.3) | 27.37 (4.4) | 28.4 (4.3) | < 0.001 |
SBP (mmHg) | 134.27 (23.3) | 144.12 (23.9) | 131.64 (22.4) | < 0.001 |
DBP (mmHg) | 81.4 (12.0) | 82.3 (14.1) | 81.23 (11.3) | 0.22 |
FPG (mg/dl) | 112.0 (47.19) | 128.83 (61.6) | 107.5 (41.4) | < 0.001 |
2Â h-PCPG (mg/dl) | 141.23 (71.9) | 154.7 (87.7) | 138.5 (67.9) | 0.012 |
Total cholesterol (mg/dl) | 235.9(48.4) | 231.16(48.9) | 237.13 (48.2) | 0.06 |
eGFR, 60 ml/min/1.73 m2 | 52.8 (6.3) | 50.3 (8.12) | 53.45 (5.6) | < 0.001 |
Pulse pressure, (mmHg) | 52.8 (18.3) | 61.8 (18.7) | 50.4 (17.4) | < 0.001 |
Hypertension medication, n (%) | 399 (27.6) | 115 (37.7) | 284 (24.8) | < 0.001 |
Smoking status, n (%) | Â | Â | Â | 0.001 |
 Never | 1131 (78.1) | 214 (70.2) | 917 (80.2) |  |
 Former | 189 (13.1) | 54 (17.7) | 135 (11.8) |  |
 Current | 128 (8.8) | 37 (12.1) | 91 (8.0) |  |
Diabetes, n (%) | 377 (26.0) | 141 (46.2) | 236 (20.6) | < 0.001 |
Hypercholesterolemia, n (%) | 1135 (78.4) | 231 (75.7) | 904 (79.1) | 0.21 |
Prevalent CVD, n (%) | 216 (14.9) | 73 (23.9) | 143 (12.5) | < 0.001 |